Orthocell

Orthocell Fixed Asset Turnover

The Fixed Asset Turnover of Orthocell (OCC.AX) as of Nov 11, 2026 is 3.24. In the previous year, Fixed Asset Turnover was 2.07 — a change of 56.17% (higher).

Fixed Asset Turnover

3.24

YoY

56.17%

Last updated:

Fixed Asset Turnover of Orthocell is 2025 3.24 . Fixed Asset Turnover of Orthocell was 2024 2.07 . It decreases by 56.17% higher compared to the previous year.

The Orthocell Fixed Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Fixed Asset Turnover
Date
Fixed Asset Turnover
Jan 1, 2018
1.82 AUD
Jan 1, 2019
3.29 AUD
Jan 1, 2020
0.98 AUD
Jan 1, 2021
1.09 AUD
Jan 1, 2022
1.09 AUD
Jan 1, 2023
2.64 AUD
Jan 1, 2024
2.07 AUD
Jan 1, 2025
3.24 AUD
The Orthocell Fixed Asset Turnover history
YEARFixed Asset TurnoverYoY
3.24+56.17%
2.07-21.46%
2.64+141.81%
1.09+0.29%
1.09+11.36%
0.98-70.29%
3.29+81.37%
1.82+22.61%
1.48-35.76%
2.30-10.73%
2.58+7.18%
2.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orthocell Stock analysis

What does Orthocell do? Orthocell Ltd develops and commercializes cell therapies and related technologies focused on regenerating mobility for patients with bone and soft tissue injuries. The company's products include CelGro, a collagen medical device using SMRT manufacturing for tissue reconstruction in dental and orthopedic applications, Striate+ for dental GBR, Remplir for peripheral nerve reconstruction, and SmrtGraft for tendon repair. Autologous cell therapy, particularly its tendon cell therapy in development in the United States, targets chronic tendon injuries through advanced injectable cellular therapy for cartilage and tendon regeneration. Orthocell's primary customers are healthcare providers and medical institutions requiring advanced tissue repair solutions. The company generates revenue through the sale of its medical devices and cell therapy products, with CelGro and related SMRT manufacturing processes forming a core part of its commercial portfolio. Its autologous tendon therapy development in the U.S. represents a key growth segment targeting chronic tendon injury treatments. The company's product portfolio is structured around regenerative medicine applications, with CelGro serving dental and orthopedic markets, Striate+ specifically for dental GBR, Remplir addressing nerve reconstruction needs, and SmrtGraft focused on tendon repair. Orthocell's commercial strategy emphasizes direct sales of these products to healthcare professionals and institutions seeking innovative solutions for tissue repair and regeneration. Orthocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orthocell stock

Fixed Asset Turnover of Orthocell is 3.24 in 2025.

Fixed Asset Turnover of Orthocell changed from 2.07 to 3.24, representing a 56.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Fixed Asset Turnover Orthocell since 2006 – with annual values, charts, and detailed analysis.

Fixed asset turnover measures revenue generated per unit of PP&E. Higher ratios indicate more efficient utilization of physical assets.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Fixed Asset Turnover's Orthocell with sector peers and the industry average to assess whether it is attractive.

To evaluate Fixed Asset Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Fixed Asset Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Orthocell

All Key Metrics — Orthocell